TITLE

The EMEA Keeps Up-to-Date

AUTHOR(S)
O'Donnell, Peter
PUB. DATE
August 2001
SOURCE
Applied Clinical Trials;Aug2001, Vol. 10 Issue 8, p18
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on the drug development regulations of the European Agency for the Evaluation of Medicinal Products (EMEA) in Europe. Conflicts on the revision of the Declaration of Helsinki; Guidance provided by EMEA for clinical investigations of Crohn's disease treatments; Advice on testing procedures of medical products during pregnancy. INSET: The EU's Rules on Clinical Trials..
ACCESSION #
5041967

 

Related Articles

  • EMA launches guidelines for development of paediatric meds.  // PharmacoEconomics & Outcomes News;8/1/2013, Issue 684, p3 

    The article reports on the new guideline from the European Medicines Agency (EMA) regarding the pharmaceutical development and accessibility of medicines for paediatric use.

  • Will clinical trial data disclosure reduce incentives to develop new uses of drugs? Price, W Nicholson; Minssen, Timo // Nature Biotechnology;Jul2015, Vol. 33 Issue 7, p685 

    A letter to the editor is presented related to adverse effects of the clinical trial data disclosure on the development of new uses of drugs in the wake of adoption of such a policy by the European Medicines Agency in October 2014.

  • The U.S. Biosimilar Pathway: Policy Precedes Science. Shoemaker, David // Applied Clinical Trials;Jun2015, Vol. 24 Issue 6/7, p40 

    The article discusses the U.S. Biosimilar Price Competition and Innovation Act (BPCIA), governing the development and approval of biosimilar drugs in the U.S. It discusses the guidance document issued by the U.S. Food and Drug Administration (FDA), to analyse the differences between small...

  • UK's Labyrinthine Regulations Stalling Regenerative Medicine. Moran, Nuala // BioWorld International;7/10/2013, Vol. 18 Issue 28, p6 

    This article focuses on the impact of problems with the regulatory framework and a lack of coordination on the development of regenerative therapies in Great Britain. These problems are delaying health and economic benefits of regenerative therapies being developed. A published report on...

  • EMA Collaborates with HTA Assessment Networks. Milmo, Sean // BioPharm International;Feb2014, Vol. 27 Issue 2, p10 

    The article deals with the decision of the European Medicines Agency (EMA) to collaborate with the European Union assessment network EUnetHTA. The collaboration covers the involvement of Health Technology Assessment (HTA) bodies in providing advice to drug makers in the early stages of a drug's...

  • FDA tows personalized line. Waltz, Emily // Nature Biotechnology;Jan2014, Vol. 32 Issue 1, p10 

    The article offers information in the report by the U.S. Food and Drug Administration (FDA), "Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development," which describes the efforts of the agency to improve its regulatory policies for personalized medicine.

  • Uncle Sam, MD. Pitts, Peter J. // Pharmaceutical Executive;Jun2005, Vol. 25 Issue 6, p46 

    The article discusses certain issues concerning the public domain of drug development and drug approval process. According to the author, placing a vaccine or cure immediately into the public domain thwarts the government's public health goal of identifying treatments or cures expeditiously....

  • FDA to regulate the use of transgenic animals.  // Nature;1/22/2009, Vol. 457 Issue 7228, p371 

    The article discusses the ruling by the U.S. Food and Drug Administration (FDA) regarding the adoption of guidelines that would regulate the use of genetically engineered animals. Topics include a brief overview of the reason for the ruling, the concern about the FDA's transparency regarding the...

  • Striking the right balance.  // Nature Reviews Drug Discovery;Nov2006, Vol. 5 Issue 11, p879 

    The recent report from the Institute of Medicine on the US systems for ensuring drug safety emphasized deficiencies in post-approval assessment of drug risks. As the drug safety debate progresses, the importance of assessing drug risks and benefits together should not be forgotten, and nor...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics